{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:18:40Z","timestamp":1781659120374,"version":"3.54.5"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI140970"],"award-info":[{"award-number":["R01 AI140970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Antiviral Drug Discovery and Development Center","award":["U19 AI142759"],"award-info":[{"award-number":["U19 AI142759"]}]},{"name":"Intramural Research Program of the"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011072","name":"University of North Carolina (UNC) Center for AIDS Research","doi-asserted-by":"publisher","award":["P30-AI050410"],"award-info":[{"award-number":["P30-AI050410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"UNC Lineberger Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30-CA016086"],"award-info":[{"award-number":["P30-CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir\/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir\/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.<\/jats:p>","DOI":"10.1093\/infdis\/jiae213","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T04:15:40Z","timestamp":1720412140000},"page":"1380-1383","source":"Crossref","is-referenced-by-count":7,"title":["Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir\/Ritonavir Resistance Mutations"],"prefix":"10.1093","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-386X","authenticated-orcid":false,"given":"Shuntai","family":"Zhou","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Long","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rosenke","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana"},{"name":"School of Biomedical Sciences, University of Plymouth"},{"name":"The Vaccine Group Ltd , Plymouth, Devon ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-0773","authenticated-orcid":false,"given":"Ronald","family":"Swanstrom","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center"},{"name":"Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"2024121523510220700_jiae213-B1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cid\/ciad685","article-title":"Review: the landscape of antiviral therapy for COVID-19 in the era of widespread population immunity and Omicron-lineage viruses","volume":"78","author":"Meyerowitz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024121523510220700_jiae213-B2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"2024121523510220700_jiae213-B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.abn0048","article-title":"Lethal mutagenesis as an antiviral strategy","volume":"375","author":"Swanstrom","year":"2022","journal-title":"Science"},{"key":"2024121523510220700_jiae213-B4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"2024121523510220700_jiae213-B5","volume-title":"COVID-19 antivirals utilization: geographic and demographic patterns of treatment in 2022","author":"Murphy","year":"2022"},{"key":"2024121523510220700_jiae213-B6","doi-asserted-by":"crossref","first-page":"e166485","DOI":"10.1172\/jci.insight.166485","article-title":"Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques","volume":"8","author":"Rosenke","year":"2023","journal-title":"JCI Insight"},{"key":"2024121523510220700_jiae213-B7","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.1128\/JVI.00522-15","article-title":"Primer ID validates template sampling depth and greatly reduces the error rate of next-generation sequencing of HIV-1 genomic RNA populations","volume":"89","author":"Zhou","year":"2015","journal-title":"J Virol"},{"key":"2024121523510220700_jiae213-B8","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1021\/acsinfecdis.2c00319","article-title":"Unique molecular identifiers and multiplexing amplicons maximize the utility of deep sequencing to critically assess population diversity in RNA viruses","volume":"8","author":"Zhou","year":"2022","journal-title":"ACS Infect Dis"},{"key":"2024121523510220700_jiae213-B9","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024121523510220700_jiae213-B10"},{"key":"2024121523510220700_jiae213-B11","doi-asserted-by":"crossref","first-page":"e01348-19","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"key":"2024121523510220700_jiae213-B12","doi-asserted-by":"crossref","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae213\/58467959\/jiae213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/6\/1380\/61141188\/jiae213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/6\/1380\/61141188\/jiae213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T23:51:17Z","timestamp":1734306677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/6\/1380\/7708850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,8]]},"published-print":{"date-parts":[[2024,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae213","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,7,8]]}}}